JOHNSON & JOHNSON JOHNSON & JOH logo

JOHNSON & JOHNSON JOHNSON & JOH (0R34)

Market Closed
17 Jan, 15:30
$
147. 00
+0.1
+0.07%
$
- Market Cap
29.06 P/E Ratio
0.33% Div Yield
7,106 Volume
9.91 Eps
$ 146.9
Previous Close
Day Range
146.42 148.3
Year Range
140.68 165.71
Earnings results expected in 1 days

Summary

0R34 closed Friday higher at $147, an increase of 0.07% from Thursday's close, completing a monthly increase of 0.85% or $1.24. Over the past 12 months, 0R34 stock gained 0.85%.
0R34 pays dividends to its shareholders, with the most recent payment made on Dec 10, 2024. The next announced payment will be in In 1 month on Mar 04, 2025 for a total of $1.24.
The last earnings report, released on 1 Hour ago, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.11%, based on the last three reports. The next scheduled earnings report is due on Jan 22, 2025.
The stock of the company had never split.
The company's stock is traded on 17 different exchanges and in various currencies, with the primary listing on LSE (USD).
Want to track 0R34 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

0R34 Chart

FAQ

What Is the JOHNSON & JOHNSON JOHNSON & JOH(0R34) Stock Price Today?

The 0R34 stock price today is $147.00.

What Stock Exchange Does JOHNSON & JOHNSON JOHNSON & JOH Trade On?

JOHNSON & JOHNSON JOHNSON & JOH is listed and trades on the NYSE.

What Is the Stock Symbol for JOHNSON & JOHNSON JOHNSON & JOH?

The stock symbol for JOHNSON & JOHNSON JOHNSON & JOH is "0R34".

Does JOHNSON & JOHNSON JOHNSON & JOH Pay Dividends? What's The Current Dividend Yield?

0R34 is not paying dividends to its shareholders.

What Is the JOHNSON & JOHNSON JOHNSON & JOH Market Cap?

As of today, JOHNSON & JOHNSON JOHNSON & JOH does not have a market cap available.

What is JOHNSON & JOHNSON JOHNSON & JOH Earnings Per Share?

The JOHNSON & JOHNSON JOHNSON & JOH EPS is 0.

What Is the Next JOHNSON & JOHNSON JOHNSON & JOH Earnings Date?

JOHNSON & JOHNSON JOHNSON & JOH will release its next earnings report on Jan 22, 2025.

Did JOHNSON & JOHNSON JOHNSON & JOH had any splits?

No, JOHNSON & JOHNSON JOHNSON & JOH has never had a stock split.

JOHNSON & JOHNSON JOHNSON & JOH Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. Joaquin Duato CEO
LSE Exchange
US4781601046 ISIN
United States Country
131,900 Employees
18 Feb 2025 Last Dividend
- Last Split
- IPO Date

Overview

Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.

Products and Services

The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:

  • Innovative Medicine:

    This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.

  • MedTech:

    This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.

Contact Information

Address: One Johnson & Johnson Plaza
Phone: 732 524 0400